Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

(2012) Joel B. Nelson et al.   CANCER

Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer

(2012) Evan Y. Yu et al.   JOURNAL OF UROLOGY

Role of the endothelin axis and its antagonists in the treatment of cancer

(2011) A Bagnato et al.   BRITISH JOURNAL OF PHARMACOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

What Do Prostate Cancer Patients Die Of?

(2011) M. Riihimaki et al.   ONCOLOGIST

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,

(2010) Nicholas D. James et al.   BJU INTERNATIONAL

Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer

(2010) Matthew R. Smith et al.   CANCER

Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications

(2008) Elahe A. Mostaghel et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

(2008) Joel B. Nelson et al.   CANCER

A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer

(2008) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

(2008) Nicholas D. James et al.   EUROPEAN UROLOGY

ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer

(2008) Ruth Warren et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS